A Phase 1 interventional study of AC-170 0.17% and AC-170 0.24% (Formulation 1) in Normal Ocular Health, sponsored by Aciex Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-14.
Sponsored by Aciex Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and comfort of AC-170 compared to a placebo.
Aciex Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AC-170 0.17%
Drug: AC-170 0.24% (Formulation 1)
Drug: AC-170 0.24% (Formulation 2)
Drug: Olopatadine hydrochloride 0.2%/Tears Naturale II
1 drop in one eye at one timepoint
1 drop in one eye at one timepoint
1 drop in one eye at one timepoint
1 drop in one eye at one timepoint
Drop Comfort Score
drop comfort on 0-10 scale
Time frame: during 3 minute period
The record gives a start of Dec 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetirizine
Aciex Therapeutics, Inc.